Q2 2024 EPS Estimates for UroGen Pharma Ltd. (NASDAQ:URGN) Raised by Analyst

UroGen Pharma Ltd. (NASDAQ:URGN) – Analysts at HC Wainwright lifted their Q2 2024 earnings estimates for UroGen Pharma in a research report issued to clients and investors on Monday, July 1st. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.77) per share for the quarter, up from their previous estimate of ($0.83). HC Wainwright has a “Buy” rating and a $60.00 price objective on the stock. The consensus estimate for UroGen Pharma’s current full-year earnings is ($3.52) per share. HC Wainwright also issued estimates for UroGen Pharma’s Q3 2024 earnings at ($0.75) EPS, Q4 2024 earnings at ($0.71) EPS, FY2024 earnings at ($3.16) EPS, Q1 2025 earnings at ($0.75) EPS, Q2 2025 earnings at ($0.78) EPS, Q3 2025 earnings at ($0.61) EPS, Q4 2025 earnings at ($0.59) EPS and FY2025 earnings at ($2.72) EPS.

UroGen Pharma (NASDAQ:URGN) last issued its earnings results on Monday, May 13th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.04). The business had revenue of $18.78 million for the quarter, compared to analysts’ expectations of $20.73 million.

URGN has been the topic of a number of other research reports. LADENBURG THALM/SH SH boosted their target price on shares of UroGen Pharma from $48.00 to $53.50 and gave the company a “buy” rating in a report on Friday, June 14th. Oppenheimer boosted their price objective on UroGen Pharma from $32.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, June 14th.

UroGen Pharma Stock Performance

URGN stock opened at $15.01 on Wednesday. The company has a market capitalization of $351.98 million, a PE ratio of -4.41 and a beta of 1.12. UroGen Pharma has a one year low of $8.69 and a one year high of $24.13. The company’s 50 day moving average price is $14.42 and its two-hundred day moving average price is $15.26.

Institutional Investors Weigh In On UroGen Pharma

Institutional investors have recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC raised its stake in shares of UroGen Pharma by 31.6% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 4,955 shares of the company’s stock worth $74,000 after purchasing an additional 1,191 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of UroGen Pharma by 65.1% in the first quarter. China Universal Asset Management Co. Ltd. now owns 5,903 shares of the company’s stock valued at $89,000 after buying an additional 2,328 shares in the last quarter. Jump Financial LLC increased its position in shares of UroGen Pharma by 12.6% in the fourth quarter. Jump Financial LLC now owns 33,320 shares of the company’s stock valued at $500,000 after buying an additional 3,720 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of UroGen Pharma by 40.4% in the fourth quarter. BNP Paribas Financial Markets now owns 22,996 shares of the company’s stock valued at $345,000 after buying an additional 6,617 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its position in shares of UroGen Pharma by 38.4% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 29,766 shares of the company’s stock valued at $417,000 after buying an additional 8,260 shares in the last quarter. Institutional investors and hedge funds own 91.29% of the company’s stock.

Insider Activity at UroGen Pharma

In other news, insider Mark Schoenberg sold 5,153 shares of the firm’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $13.08, for a total transaction of $67,401.24. Following the transaction, the insider now owns 144,284 shares in the company, valued at $1,887,234.72. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 11.13% of the stock is currently owned by insiders.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.